Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman
3033PDF: 1555HTML: 385 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2428PDF: 808HTML: 8786Efremov 1: 204Efremov 2: 161 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
1963PDF: 1576HTML: 344 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2796PDF: 1388HTML: 3037Cover Letter: 180 -
Acquired Hemophilia A successfully treated with rituximab
1836PDF: 1087HTML: 1443Figure 1: 150 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3410PDF: 1571HTML: 2660 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
1937PDF: 1808HTML: 324 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
714PDF: 848Suppl. Files: 109HTML: 61 -
MUTATIONAL PROFILES OF F8 AND F9 IN A COHORT OF HAEMOPHILIA A AND HAEMOPHILIA B PATIENTS IN THE MULTI-ETHNIC MALAYSIAN POPULATION
1950PDF: 1011HTML: 653Figure 1: 122Figure 2: 140 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3226PDF: 1424HTML: 3970 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4231PDF: 1446HTML: 1528Untitled: 207 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2393PDF: 755HTML: 1719 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1859PDF: 702HTML: 677 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2160PDF: 1001HTML: 1971Characteristic of study group: 175 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277512PDF: 1743HTML: 3835 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2740PDF: 1182HTML: 2665Figure 1: 143 -
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
1760PDF: 775HTML: 3580 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3719Suppl. Files: 1029PDF: 1016Html: 104 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
1947PDF: 1445HTML: 256 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
3755PDF: 1402HTML: 8483 -
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19
3166PDF: 1482HTML: 390 -
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
960PDF: 959HTML: 87 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1515PDF: 772HTML: 136 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4193PDF: 1688HTML: 1094 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1414PDF: 888HTML: 207 -
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
1723PDF: 776HTML: 10202Figures 1,2,3: 150 -
-
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1148PDF: 912HTML: 187 -







